Therapeutic potential of TGF-β-induced CD4+ Foxp3 + regulatory T cells in autoimmune diseases

Xiaohui Zhou; Ning Kong; Hejian Zou; David Brand; Xianpei Li; Zhongmin Liu; Song Guo Zheng

doi:10.3109/08916931003782163

Therapeutic potential of TGF-β-induced CD4⁺ Foxp3 ⁺ regulatory T cells in autoimmune diseases

Xiaohui Zhou, Ning Kong, Hejian Zou, David Brand, Xianpei Li, Zhongmin Liu, Song Guo Zheng

Department of Medicine

Research output: Contribution to journal › Review article › peer-review

59 Scopus citations

Abstract

Foxp3⁺ T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-β-induced CD4M⁺ Foxp3 ⁺ cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-β are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.

Original language	English (US)
Pages (from-to)	43-50
Number of pages	8
Journal	Autoimmunity
Volume	44
Issue number	1
DOIs	https://doi.org/10.3109/08916931003782163
State	Published - Feb 2011

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology

Access to Document

10.3109/08916931003782163

Cite this

@article{f82ee323fcad4342aaea40df96977cf3,

title = "Therapeutic potential of TGF-β-induced CD4+ Foxp3 + regulatory T cells in autoimmune diseases",

abstract = "Foxp3+ T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-β-induced CD4M+ Foxp3 + cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4+ CD25+ Foxp3+ regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-β are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.",

author = "Xiaohui Zhou and Ning Kong and Hejian Zou and David Brand and Xianpei Li and Zhongmin Liu and Zheng, {Song Guo}",

note = "Funding Information: This work was supported by grants (NIH/NIAMS grant R01AR059103) from the Arthritis Foundation, Outstanding Youth Scientist Award from National Nature Science Foundation of China (30728007), and the American College of Rheumatology “Within Our Reach” grant.",

year = "2011",

month = feb,

doi = "10.3109/08916931003782163",

language = "English (US)",

volume = "44",

pages = "43--50",

journal = "Autoimmunity",

issn = "0891-6934",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Therapeutic potential of TGF-β-induced CD4+ Foxp3 + regulatory T cells in autoimmune diseases

AU - Zhou, Xiaohui

AU - Kong, Ning

AU - Zou, Hejian

AU - Brand, David

AU - Li, Xianpei

AU - Liu, Zhongmin

AU - Zheng, Song Guo

N1 - Funding Information: This work was supported by grants (NIH/NIAMS grant R01AR059103) from the Arthritis Foundation, Outstanding Youth Scientist Award from National Nature Science Foundation of China (30728007), and the American College of Rheumatology “Within Our Reach” grant.

PY - 2011/2

Y1 - 2011/2

N2 - Foxp3+ T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-β-induced CD4M+ Foxp3 + cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4+ CD25+ Foxp3+ regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-β are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.

AB - Foxp3+ T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-β-induced CD4M+ Foxp3 + cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4+ CD25+ Foxp3+ regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-β are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=78751499888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751499888&partnerID=8YFLogxK

U2 - 10.3109/08916931003782163

DO - 10.3109/08916931003782163

M3 - Review article

C2 - 20670119

AN - SCOPUS:78751499888

SN - 0891-6934

VL - 44

SP - 43

EP - 50

JO - Autoimmunity

JF - Autoimmunity

IS - 1

ER -

Therapeutic potential of TGF-β-induced CD4⁺ Foxp3 ⁺ regulatory T cells in autoimmune diseases

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this